Literature DB >> 15039117

Psychosine-induced apoptosis in a mouse oligodendrocyte progenitor cell line is mediated by caspase activation.

Mariam Zaka1, David A Wenger.   

Abstract

Globoid cell leukodystrophy (GLD) is an inherited neurological disorder caused by the deficiency of galactocerebrosidase (GALC) activity resulting in cell death of oligodendrocytes and subsequent demyelination. The death of oligodendrocytes is accompanied by accumulation of psychosine, which is also a substrate for the GALC enzyme. In this report, we investigated the mechanism of the toxic effect of psychosine in a mouse-derived oligodendrocyte progenitor cell line (OLP-II), a precursor to the cell type most affected in GLD. Psychosine caused cytotoxicity in a dose-dependent manner. Lower concentration of psychosine (5 microM) did not significantly reduce OLP-II cell numbers. However, 50 microM psychosine induced up to 45% cell death. These results were confirmed by the Tunel assay, which is a hallmark for the detection of apoptosis. Moreover, psychosine treatment resulted in the activation/cleavage of initiator caspase-8 and -9, and effector caspase-3. These results support a role for psychosine in OLP-II cell death via an apoptotic mechanism, and suggest the involvement of caspases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039117     DOI: 10.1016/j.neulet.2003.12.126

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  36 in total

1.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

2.  Effects of irradiation on the postnatal development of the brain in a genetic mouse model of globoid cell leukodystrophy.

Authors:  Francesca Galbiati; Giulia Clementi; Daniela Superchi; Maria I Givogri; Ernesto R Bongarzone
Journal:  Neurochem Res       Date:  2007-01-03       Impact factor: 3.996

Review 3.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 4.  A microglial hypothesis of globoid cell leukodystrophy pathology.

Authors:  Alexandra M Nicaise; Ernesto R Bongarzone; Stephen J Crocker
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

5.  Lysosomal storage diseases: heterogeneous group of disorders.

Authors:  David A Wenger; Paola Luzi; Mohammad A Rafi
Journal:  Bioimpacts       Date:  2013-12-02

6.  Axonopathy is a compounding factor in the pathogenesis of Krabbe disease.

Authors:  Ludovico Cantuti Castelvetri; Maria Irene Givogri; Hongling Zhu; Benjamin Smith; Aurora Lopez-Rosas; Xi Qiu; Richard van Breemen; Ernesto Roque Bongarzone
Journal:  Acta Neuropathol       Date:  2011-03-04       Impact factor: 17.088

7.  Effect of vitamin D3 intake on the onset of disease in a murine model of human Krabbe disease.

Authors:  Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  J Neurosci Res       Date:  2014-09-19       Impact factor: 4.164

8.  Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.

Authors:  Jameson J Ribbens; Ann B Moser; Walter C Hubbard; Ernesto R Bongarzone; Gustavo H B Maegawa
Journal:  Mol Genet Metab       Date:  2013-09-21       Impact factor: 4.797

9.  Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).

Authors:  Richard E Connon; Juergen Geist; Janice Pfeiff; Alexander V Loguinov; Leandro S D'Abronzo; Henri Wintz; Christopher D Vulpe; Inge Werner
Journal:  BMC Genomics       Date:  2009-12-15       Impact factor: 3.969

10.  Oxidative stress as a therapeutic target in globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Elizabeth Y Qin; Adarsh S Reddy; Carole A Vogler; Mark S Sands
Journal:  Exp Neurol       Date:  2012-07-28       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.